The U.S. Food and Drug Administration (FDA) approved Vioxx in May 1999 for use in reducing pain and inflammation from osteoarthritis, acute pain in adults and for the treatment of premenstrual syndrome.
The FDA later expanded its approval of Vioxx to include treatment for rheumatoid arthritis in both adults and children.
For over five years, Merck & Co. engaged in one of the largest sampling programs ever.
The drug company dedicated millions of dollars to direct marketing and advertising in order to secure a competitive market share.
As of 2003, Merck & Co. reported approximately $2.5 billion in sales and about 25 million Americans receiving Vioxx prescriptions.